Ratos: Interim report January-September 2011

Regulatory Information 2011-11-09

This information is disclosed in accordance with the Securities Markets Act, the
    Financial Instruments Trading Act or demands made in the exchange rules.

  * Profit before tax SEK 935m (2,047)
  * Earnings per share before dilution SEK 2.21 (4.93)
  * Mixed development in the holdings - half with positive trend, half less
    favourable development
  * Add-on acquisition of Sophion Bioscience
  * Medisize sold - exit gain SEK 38m
  * Total return on Ratos shares -33%

Telephone conference at 10.00 CET, tel +46 8 505 201 14.
Stockholm 9 November 2011
Ratos AB (publ)
For further information:
Arne Karlsson, CEO, +46 8 700 17 00
Emma Rheborg, Head of Corporate Communications & IR, +46 8 700 17 20
Financial calendar from Ratos:
 Year-end report 2011                    16 February 2012
 Annual General Meeting                  18 April 2012
 Interim Report January - March 2012     8 May 2012
 Interim Report January - June 2012      17 August 2012
 Interim Report January - September 2012 9 November 2012

Ratos is a private equity conglomerate. The company's mission is to maximise
shareholder value over time through the professional, active and responsible
exercise of its ownership role in primarily medium to large unlisted Nordic
companies. Ratos's holdings include AH Industries, Anticimex, Arcus-Gruppen,
Biolin Scientific, Bisnode, Contex, DIAB, Euromaint, Finnkino, GS-Hydro, Hafa
Bathroom Group, HL Display, Inwido, Jøtul, KVD Kvarndammen, Lindab, Mobile
Climate Control, SB Seating and Stofa. Ratos is listed on Nasdaq OMX Stockholm
and market capitalisation amounts to approximately SEK 27 billion.